本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

0.0030
0.0000
成交量:- -
成交額:- -
市值:20.40萬
市盈率:-0.01
高:0.0030
開:0.0030
低:0.0030
收:0.0030
52周最高:0.1760
52周最低:0.0030
股本:6,800.36萬
流通股本:6,800.36萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-0.4722
淨資產收益率:-53.85%
總資產收益率:-23.19%
市淨率:0.01
市盈率(LYR):- -

資料載入中...

2023/01/04

重要事件披露

Form 8-K - Current report
2022/11/14

重要事件披露

Form 8-K - Current report
2022/11/14

重要事件披露

Form 8-K - Current report
2022/11/14

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2022/10/13

SEC問詢函

Form CORRESP - Correspondence
2022/10/06

招股説明書

Form S-1 - General form for registration of securities under the Securities Act of 1933
2022/09/12

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2022/09/07

重要事件披露

Form 8-K - Current report
2022/08/15

重要事件披露

Form 8-K - Current report
2021/06/16

重要事件披露

8-K - Current report
2021/06/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/06/03

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/06/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/05/25

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/05/19

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/05/17

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/05/10

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2021/05/10

重要事件披露

8-K - Current report
2021/05/07

重要事件披露

8-K - Current report
2021/05/07

[修訂]年度報告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]